Danaher Corporation (DHR)
Market Cap | 173.32B |
Revenue (ttm) | 22.28B |
Net Income (ttm) | 3.51B |
Shares Out | 706.20M |
EPS (ttm) | 4.89 |
PE Ratio | 49.32 |
Forward PE | 30.96 |
Dividend | $0.72 |
Dividend Yield | 0.30% |
Trading Day | April 19 |
Last Price | $240.94 |
Previous Close | $243.06 |
Change ($) | -2.12 |
Change (%) | -0.87% |
Day's Open | 241.84 |
Day's Range | 239.95 - 242.72 |
Day's Volume | 830,203 |
52-Week Range | 150.80 - 248.62 |
Danaher (DHR) benefits from strength across its businesses, acquisitions and shareholder-friendly policies. However, rising costs and expenses remain concerning.
Danaher (DHR) raises revenue projection for the first quarter of 2021 on strengthening Diagnostics and Life Sciences businesses.
Danaher (DHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the n...
SSUMY vs. DHR: Which Stock Is the Better Value Option?
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
WASHINGTON, April 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced today that it expects first quarter 2021 core revenue growth to be above the high-end of the Company'...
Although Friday is set for mixed trading, the indices are set to close the week with solid gains as the S&P continues hovering around a record high. Meanwhile, Q.ai's deep learning algorithms have broug...
WASHINGTON, March 25, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2021 on Thursday, April 22, 2021 be...
BREA, Calif., March 23, 2021 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today announced that its Access SARS-CoV-2 IgG II antibody assay received U.S. Emergency Use Authorization (E...
BREA, Calif., March 18, 2021 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today announced their commitment to support the U.S. government's plan to invest more than $12 billion to exp...
CORALVILLE, Iowa--(BUSINESS WIRE)--Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, announced today the acquisition of Swift Biosciences, a pioneer in the developm...
WASHINGTON, March 4, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Barclays Global Heal...
We have narrowed down our search to five corporate behemoths that suffered a blow in last month's turmoil. These are AAPL, MSFT, FB, ABT and DHR.
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Danaher (DHR) is poised to benefit from growth opportunities within its segments. Also, gains from acquired assets and divestments as well as shareholder-friendly policies are likely to favor.
WASHINGTON, Feb. 23, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.21 per share of its common stoc...
WASHINGTON, Feb. 22, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Cowen Healthcare Conference on ...
Players in the Zacks Diversified Operations industry are leveraging the pandemic-induced demand in the medical equipment and personal safety products markets. Also, strengthening businesses in markets l...
Introduction: What is lean manufacturing?
The key to the stock's prospects will be to continue its earnings trajectory in a post-COVID-19 world.
Danaher Corporation (DHR) CEO Rainer Blair on Q4 2020 Results - Earnings Call Transcript
Danaher's (DHR) Q4 results reflect strength in Diagnostics, Life Sciences, and Environmental & Applied Solutions segments as well as growth in margins. Core sales growth projections are impressive.
Danaher (DHR) delivered earnings and revenue surprises of 13.04% and 0.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
WASHINGTON, Jan. 28, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2020. All results in this release reflect only cont...
Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
It's not easy to beat every quarter on earnings for five years, including during a global pandemic. These companies have done it.
Danaher (DHR) Q4 results to reflect benefits from solid Diagnostics and Life Sciences demand. Also, positive impacts of acquired assets and foreign currency translations are likely to have aided.
The Danaher Corporation uses a continuous improvement strategy called the Danaher Business System. After starting as a Lean Manufacturing practice, it evolved and expanded into a system that affects eve...
Danaher Corporation (DHR) CEO Rainer Blair Presents at J.P. Morgan Healthcare Conference Call Transcript
WASHINGTON, Jan. 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment today on the Company's f...
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
WASHINGTON, Jan. 7, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conferenc...
WASHINGTON, Jan. 7, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2020 on Thursday, January 28, 2021 b...
Water doesn't typically get the same focus that I put on other utilities like electric and gas companies. Though, that doesn't mean that investing in water ETFs doesn't have its own merits; it certainly...
WASHINGTON, Dec. 21, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that Jose-Carlos ("JC") Gutierrez-Ramos has been named Senior Vice President and Chief Scientific Officer for Da...
We have narrowed down our search to five corporate behemoths that have popped more than 30% year to date. These are: NVDA, DHR, UPS, MSFT and AVGO.
Three well-run companies and what investors can take away from their outperformance in the past decade.
Danaher Corporation (DHR) CEO Rainer Blair Presents at Evercore ISI 3rd Annual HealthCONx Brokers Conference (Transcript)
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...
Science and technology company Danaher Corporation (NYSE: DHR) boasts a high-quality and defensive portfolio that has become "less compelling to own" ahead of a cyclical recovery into 2021, according to...
WASHINGTON, Nov. 24, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Confere...
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to t... [Read more...]
Industry Diagnostics & Research | Founded 1969 |
CEO H. Lawrence Culp | Employees 67,000 |
Stock Exchange NYSE | Ticker Symbol DHR |
Financial Performance
In 2020, Danaher's revenue was $22.28 billion, an increase of 24.42% compared to the previous year's $17.91 billion. Earnings were $3.65 billion, an increase of 21.21%.
Analyst Forecasts
According to 21 analysts, the average rating for Danaher stock is "Buy." The 12-month stock price forecast is 269.12, which is an increase of 11.70% from the latest price.